QuantalX is unusually well-positioned in functional neurodiagnostics, combining TMS and EEG to generate objective brain-network maps against a normative database — a methodology more akin to functional neuroimaging than standard EEG assessment. Its FDA De Novo authorization establishes a new device category, creating a potential regulatory moat, and Breakthrough Device designations for two indications accelerate its clinical credibility relative to comparably sized companies.